MorphoSys AG: Announcement of the Convening of the AGM in Munich/Germany on 23 May 2014 according to sec. 121 para. 4a AktG with the objective of Europe-wide distribution

        Print
| Source: MorphoSys AG

Martinsried / Munich, Germany, April 11, 2014 (GLOBE NEWSWIRE) --

MorphoSys AG
Martinsried/Planegg
Securities Code Number: 663200
ISIN: DE0006632003

Convenience Translation:
The text decisive for the invitation to the Annual General Meeting of MorphoSys AG is the one written in the German language.

Invitation to the Annual General Meeting 2014 of MorphoSys AG

We hereby invite the shareholders of our Company to the Annual General Meeting which is taking place on Friday, 23 May 2014 at 10:00 a.m., in the Conference Center Munich, Hanns-Seidel-Stiftung, Lazarettstraße 33, 80636 Munich.

Agenda

  1. Presentation of the adopted financial statements and the approved consolidated financial statements as of 31 December 2013, the management reports including the report of the Supervisory Board for the 2013 financial year and the explanatory report of the Management Board regarding the disclosures pursuant to section 289 para. 4, 315 para. 4 German Commercial Code (HGB)
  2. Resolution on the use of the accumulated profit of MorphoSys AG for the 2013 financial year
  3. Resolution on the formal approval of the activities of the members of the Management Board in respect of the 2013 financial year
  4. Resolution on the formal approval of the activities of the members of the Supervisory Board in respect of the 2013 financial year
  5. Resolution on the appointment of the auditor for the 2014 financial year 
  6. Resolution on the cancellation of the Conditional Capital 1999-I and the Conditional Capital 2008/II as well as the reduction of Conditional Capital 2003-II; amendments of the Articles of Association
  7. Resolution on the creation of a new Authorized Capital 2014-I with the possibility to exclude pre-emptive rights of the shareholders; amendment of the Articles of Association
  8. Resolution on the election of a Supervisory Board member
  9. Resolution regarding the authorization to purchase treasury shares pursuant to Section 71 para. 1 no. 8 of the German Stock Corporation Act and to use treasury shares with the possibility to exclude pre-emptive rights of the shareholders
  10. Resolution regarding the remuneration of the Supervisory Board 

Please find the full text of the invitation here: www.morphosys.com/agm

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR

Mario Brkulj
Associate Director Corporate Communications & IR

Alexandra Goller
Specialist Corporate Communications & IR

Jessica Rush
Specialist Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

HUG#1775599